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Thrombotic and Infectious Risks of Parenteral Nutrition in 
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Michael D. Kappelman, MD, MPH*,†
Background: Malnutrition is common in inflammatory bowel disease (IBD), requiring timely and sufficient nutritional supplementation. In 
patients hospitalized for active disease, symptoms and/or altered intestinal function hinder enteral nutrition feasibility. In this scenario, parenteral 
nutrition (PN) is used. We aimed (1) to assess the frequency of PN use between 1997 and 2012 among hospitalized pediatric patients with IBD, 
(2) to determine the risk of in-hospital thrombus and infection associated with PN, and (3) to identify predictors of thrombus and infection in
pediatric IBD hospitalizations utilizing PN.
Methods: We performed a cross-sectional analysis of pediatric patients hospitalized between 1997 and 2012. We used the Kids’ Inpatient 
Database (KID) to identify pediatric patients (≤18 years of age) with Crohn’s disease (CD) or ulcerative colitis (UC), PN exposure, and primary 
outcomes including thrombus and infection. We used multivariable regression to identify risk factors for outcomes of interest.
Results: Parenteral nutrition was utilized in 3732 (12%) of 30,914 IBD hospitalizations. Three percent of PN patients experienced a thrombotic 
complication, and 5.5% experienced an infectious complication. Multivariate analysis showed PN as an independent risk factor for thrombus 
(odds ratio [OR], 4.3; 95% confidence interval [CI], 3.2–5.6) and infection (OR, 3.8; 95% CI, 3.1–4.6). Surgery was an independent risk factor for 
thrombus (OR, 2.0; 95% CI, 1.4–2.7) and infection (OR, 2.5; 95% CI, 2.0–3.1) in hospitalizations exposed to PN.
Conclusions: Hospitalized pediatric IBD patients, particularly surgical, receiving PN are at increased risk for thrombosis and infection. 
Clinicians must balance these risks with the benefits of PN.
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INTRODUCTION
Malnutrition is common in inflammatory bowel disease 
(IBD), requiring timely and sufficient nutritional supplementa-
tion. In patients hospitalized for active disease, disease symp-
toms and/or altered intestinal function may hinder enteral 
nutrition feasibility. In this scenario, parenteral nutrition (PN) 
is used.1 Yet, the benefits of PN must be weighed against the 
risks, including thrombus formation2 and systemic infections,3 
associated with using central venous lines (CVLs) for paren-
teral infusion. Additionally, these risks may be potentiated in 
patients with IBD due to the hypercoagulable state,4–6 use of 
immunosuppressive therapy,7, 8 and frequent malnutrition.9
Although the IBD-specific risks of PN on inpatient 
thrombus (2%–72%10–12) and infection (0.4–13.3/1000 cathe-
ter-days13) have been established in adult populations, the mag-
nitude of these risks in children with IBD is likely to be quite 
different given differing age ranges and comorbidity profiles. 
Therefore, quantifying the absolute risks of PN in the hospi-
talized pediatric IBD population is needed to inform clinical 
decision-making. In this study, we leveraged a large national 
pediatric inpatient database (Kids’ Inpatient Database [KID]) 
to accomplish the following aims: (1) to assess time trends in 
the frequency of PN use among hospitalized pediatric patients 
with IBD, (2) to determine the risk of in-hospital thrombus 
and infection associated with PN use, and (3) to identify fac-
tors predictive of these adverse events in pediatric IBD hospi-
talizations initiating PN.
METHODS
Study Design and Data Source
We performed a cross-sectional analysis using 1997–2012 
data from the Kids’ Inpatient Database (KID), a nationally 
representative sample of pediatric hospitalizations from the 
Healthcare Cost and Utilization Project (HCUP), sponsored 
by the Agency for Healthcare Research and Quality (AHRQ). 
KID is the largest publicly available all-payer pediatric 
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inpatient database from the United States and includes data 
from 2–3 million yearly hospitalizations from 1997–2012 
HCUP.14 Utilizing data from up to 44 states depending on the 
year analyzed, the KID is designed to be nationally representa-
tive of pediatric hospital inpatient stays. The database contains 
more than 75 clinical and nonclinical variables, 25 International 
Classification of Diseases, 9th Revision, Clinical Modification 
(ICD-9-CM) diagnostic and procedure codes, hospital charac-
teristics, and outcomes.14
Study Sample
We examined discharge data from hospitalizations of 
patients age 18  years and younger. Hospitalizations with an 
ICD-9-CM diagnostic code indicating CD (555.xx) or UC (556.
xx) at position #1 (primary diagnosis) were eligible for inclu-
sion in this study. In addition, any hospitalization with an ICD-
9-CM diagnostic code indicating CD (555.xx) or UC (556.xx) at 
diagnostic code position #2 or position #3 was included when
the primary diagnosis was consistent with an IBD hospitaliza-
tion. For all hospitalizations where CD or UC was in position
#2 or #3, the primary diagnoses that occurred at a frequency
of 0.5% or greater were reviewed by 2 pediatric gastroenterol-
ogists and classified as “consistent with IBD hospitalization”
or “unlikely to be related to an IBD hospitalization.” Similar
inclusion/exclusion rules have been used in prior HCUP study
publications.15, 16 A  final list of codes considered “consistent
with an IBD hospitalization” can be found in Supplementary
Table 1. Diagnoses with frequencies of less than 0.5% were not
reviewed.
Exposure of Interest
The primary exposure was the use of PN during hospi-
talization, identified by the ICD-9 procedural code 99.15. This 
code includes PN administration through both central and 
peripheral catheters.
Outcomes of Interest
We identified outcomes of PN-associated thrombi and 
infections based on discharge ICD-9-CM codes. We made the 
a priori decision to evaluate the following thrombotic out-
comes: venous or arterial thrombus or embolism of the upper 
and lower limbs, thrombophlebitis, septic embolism, pulmo-
nary embolism, and embolism or other vascular complications 
due to transfusion, infusion, or perfusion. No events of septic 
emboli occurred in the data. We did not evaluate cardiovascu-
lar outcomes such myocardial infarction, stroke, or mesenteric 
ischemia, as these events can be associated with inciting events 
other than thrombus in children. We made the a priori decision 
to evaluate the following infections deemed likely to be related 
to central lines and/or the use of PN: sepsis, bacteremia, sep-
ticemia, viremia, systemic inflammatory response syndrome 
(SIRS), endocarditis, venous catheter infection, cellulitis, and 
infection/sepsis/septicemia associated with infusion. A final list 
of included codes for thrombus and infection can be found in 
Supplementary Tables 2 and 3, respectively. We also analyzed 
a composite outcome of “any complication,” as defined by 
any of the above thrombus or infection codes. Hospital dis-
charges with both infection and thrombus discharge codes were 
included only once in the composite outcome.
Covariates
We evaluated patient demographics, including age, sex, 
race, IBD abdominal hospitalization with abdominal surgery, 
and primary insurance/payer for the hospitalization. We cat-
egorized age as <6  years, 6–12  years, and 13–18  years. We 
defined race using uniform coding provided by HCUP, where 
Hispanic patients were uniquely identified without use of a 
Hispanic modifier code. We combined Asian, Pacific Islander, 
and Native American ethnicities into a single category based 
on low individual sample frequencies. We defined payer type 
as Medicaid, private/HMO, or other. Other combined “no 
charge,” “Medicare,” and “self-pay.” Hospitalization with 
abdominal surgery was defined as the presence or absence of 
ICD-9 procedural coding for small or large bowel procedures. 
We also analyzed hospital-level characteristics including loca-
tion and teaching status (rural, urban nonteaching, or urban 
teaching). A  complete list of abdominal surgical procedural 
codes can be found in Supplementary Table 4.
Statistical Analysis
All analyses were performed using SAS, version 9.4 (SAS 
Institute, Cary, NC, USA). Descriptive statistics included fre-
quency counts. We used univariate and bivariate analyses to 
quantify absolute risk, risk difference, and number needed to 
harm (NNH). We used the chi-square test for bivariate analysis 
of association between categorical variables. We summarized 
parametric continuous variables with mean and standard devi-
ation and summarized nonparametric data using median and 
interquartile range (IQR). We used a Cochran-Armitage test of 
trend for analysis of triennial prevalence of parenteral nutrition 
in pediatric IBD hospitalizations.
We used multivariable logistic regression to evaluate the 
association between the primary predictor, PN exposure, and 
the individual outcomes of thrombus, infection, and composite 
complication. We controlled for covariates including age, sex, 
race, disease type, hospitalization with abdominal surgery, year, 
payer type, and hospital type. Interaction terms for year*PN 
and for abdominal surgery*PN were included in the model and 
were not statistically significant. Odds ratios (ORs) and 95% 
confidence intervals (CIs) are presented. We constructed sepa-
rate models for CD and UC hospitalizations and a model for 
overall IBD hospitalizations. All covariates were selected a pri-
ori based on clinical relevance and previously published litera-
ture.5, 6, 8, 13, 17
We developed a second set of models using multivariable 
logistic regression to evaluate risk factors for outcomes of throm-
bus, infection, and composite complication in hospitalizations 
exposed to PN. Covariates included hospitalization with abdomi-
nal surgery, year, age, sex, race, payer type, and hospital type. As 
above, we constructed unique models for CD, UC, and IBD overall.
A 2-tailed P value of 0.05 was chosen as the threshold for 
statistical significance in bivariate analysis and multivariable 
regression.
Ethical Considerations
Due to the de-identified nature of the data, this study was 
determined exempt from review by the University of North 
Carolina Institutional Review Board (IRB).
RESULTS
We identified 30,914 hospitalizations of pediatric patients 
with IBD in the 1997–2012 KID database. Of these, 19,158 
(62%) hospitalizations were for CD, and the remaining were for 
UC. The median age of the study sample (IQR) was 15 (12–17) 
years. Approximately half  of the IBD patient hospitalizations 
occurred in females (49%). Just under three-quarters of the 
IBD hospitalizations were in Caucasians (71%), and the larg-
est contributing payer type was private/HMO insured (71%). 
Inflammatory bowel disease hospitalizations in this sample 
occurred most frequently at urban teaching centers (74%).
Use of Parenteral Nutrition
Parenteral nutrition was utilized in 3732 (12%) pediatric 
IBD hospitalizations (2363 CD and 1369 UC). Table  1 sum-
marizes discharge characteristics for pediatric IBD hospital-
izations involving PN and those not involving PN. As shown 
in Figure  1, the prevalence of PN during hospitalization for 
pediatric patients with IBD did not differ in the triennial 
intervals between 1997 and 2012 (P = 0.78). Patients hospital-
ized with CD were no more likely to receive PN than patients 
TABLE 1. Clinical and Demographic Characteristics of Pediatric IBD Hospitalizations Using the KID Database from 
1997–2012
Characteristics PN (n = 3732) No PN (n = 27,182) Total (n = 30,914)
Median IQR Median IQR Median IQR
Age, y 15 12–16 15 12–17 15 12–17
No. % No. % No. %
Age categories, y
 <6 208 5.6 1301 4.8 1509 4.9
 6–12 891 23.8 6006 22.1 6897 22.3
 12–18 2633 70.6 19,875 73.1  22,508 72.8
Female 1796 48.1 13,494 49.6 15,290 49.4
Race
 White 2267 60.7 15,565 57.2 17,832 57.7
 Black 406 10.8  2919 10.7 3325 10.7
 Hispanic 252 6.7 1992 7.4 2244 7.3
 Other 206 5.6 1259 4.7 1465 4.8
 Missing 601 16.2 5447 20 6048 19.5
Payer type
 Medicaid 717 19.3 5967 21.9 6684 21.7
 Private/HMO 2751 73.7 19,259 70.9 22,010 71.2
 Other 257 6.9 1902 7 2159 6.9
 Missing 7 0.1 54 0.2 61 0.2
Presence of a surgical procedure 836 16 4396 84 5232 16.9
Hospital type
 Rural 94 2.5 1334 4.9 1428 4.6
Urban/nonteaching 398 10.6 5152 18.9 5550 17.9
 Urban/teaching 3086 82.8 19,924 73.4 23,010 74.4
Missing 154 4.1 772 2.8 926 3.1
Disease type
 CD 2363 63.3 16,795 61.7 19,158 61.9
 UC 1369 36.7 10,387 38.2 11,756 30.1
hospitalized with UC (12.3% vs 11.6%; P = 0.07). For CD, UC, 
and IBD overall, patients hospitalized with abdominal surgical 
procedures were more likely to receive PN (P < 0.01 for all).
Thrombus
Thrombus occurred in 115 pediatric IBD hospitalized 
patients receiving PN, yielding an absolute risk of 3%. The 
most common discharge diagnosis codes for thrombi in this 
population were acute venous embolism of the upper extrem-
ity (35%), thrombophlebitis (28%), and pulmonary embolism 
(22%). In contrast, the absolute risk of thrombus in non-PN-
treated patients was 0.6%. This resulted in a risk difference of 
2.4% (95% CI, 1.8–3.0) and a corresponding number needed to 
harm of 42. Table 2 illustrates outcome by disease type.
Adjusted analysis demonstrated an increased risk for 
thrombus in PN-treated patients as compared with those not 
receiving PN (CD: OR, 5.8; 95% CI, 3.9–8.5; UC: OR, 3.6; 95% 
CI, 2.2–4.9; IBD: OR, 4.3; 95% CI, 3.2–5.6) (Table 3A).
Infection
Infection occurred in 207 pediatric IBD hospitaliza-
tions receiving PN, resulting in an absolute risk of 5.5%. The 
most common discharge diagnosis codes for infection in this 
population were septicemia (35%), cellulitis (26%), and cath-
eter-associated infections (14%). In contrast, the absolute risk 
of infection associated with hospitalizations not exposed to PN 
was 1.4%. The risk difference was 4.1% (95% CI, 3.4%–4.9%), 
with a number needed to harm of 24 hospitalizations.
Adjusted analysis demonstrated an increase in the risk of 
infection in PN-treated patients, as compared with those not 
receiving PN (CD: OR, 3.5; 95% CI, 2.8–4.5; UC: OR, 4.4; 95% 
CI, 3.1–6.1; IBD: OR, 3.8; 95% CI, 3.1–4.6) (Table 3B).
Complication
The absolute risk of either thrombus or infection (com-
posite outcome) was 8% among pediatric IBD hospitalizations 
receiving PN. The absolute risk of either event in non-PN-
treated hospitalizations was 2%, resulting in a risk difference of 
6% (95% CI, 5.2%–6.9%) and a number needed to harm of 17 
hospitalizations.
Adjusted analysis demonstrated an increase in the risk 
of complication associated with pediatric IBD hospitalizations 
receiving PN, as compared with those not receiving PN (CD: 
OR, 3.9; 95% CI, 3.1–4.8; UC: OR, 3.9; 95% CI, 3.0–5.1; IBD: 
OR, 3.9; 95% CI, 3.3–4.6) (Table 3C).
Risk Factor for Thrombus and/or Infection in 
Hospitalizations Associated With PN
Among pediatric hospitalizations for IBD involving PN, 
we next analyzed the effects of age, gender, race, payer type, 
hospital type, year, and the presence of abdominal surgery on 
inpatient events of thrombus or infection. Only hospitalizations 
with abdominal surgery were a consistent and independent risk 
factor for these outcomes. A total of 5232 (16%) pediatric IBD 
hospitalizations involved an abdominal surgical procedure. Of 
these, 3067 (58.6%) occurred in CD hospitalizations, and the 
remaining 2165 (41.4%) occurred in UC hospitalizations. After 
controlling for age, sex, race, payer type, year, and hospital 
type, hospitalizations with abdominal surgery were associated 
with an increased risk of thrombus (OR, 1.9; 95% CI, 1.2–3.0), 
TABLE 2. Number of Events of Interest and Absolute Risk According to Disease Type and Exposure Status
Crohn’s Disease Ulcerative Colitis
Outcome PN No PN Total PN No PN Total
No. % No. % No. % No. % No. % No. %
Thrombus 68 2.8 83 0.5 151 0.8 47 3.4 103 1.0 150 1.2
Infection 133 5.6 253 1.5 386 2.0 74 5.4 131 1.2 205 1.7
Complication 186 7.8  330 0.9 516 2.6 116 8.4 226 2.1 342 2.9
Total sample 2363 16,795 19,158 1369 10,387 11,756
“Total sample” represents the entire study sample size for disease type and exposure status from the KID Inpatient Database from 1997 to 2012.
FIGURE 1. Triennial prevalence of PN in pediatric IBD hospitalizations 
using the 1997–2012 KID database (P = 0.78). Point prevalence and 95% 
CI demonstrate a consistent prevalence from 1997 to 2012. 
infection (OR,  2.3; 95% CI, 1.6–3.2), and overall complica-
tion (OR, 2.1; 95% CI, 1.5–2.7) (Table 4). After stratifying by 
CD and UC, all associations remained statistically significant, 
with the exception of thrombus among CD and UC patients, 
for which we observed a consistent numeric trend (OR,  1.8; 
95% CI, 1.0–3.4; and OR, 2.0; 95% CI, 1.0–4.1, respectively). 
Supplementary Table 5A–C provides the effect estimates for the 
other covariates.
DISCUSSION
In a nationally representative sample of pediatric hos-
pitalizations, we found that PN was utilized in approximately 
12% of IBD hospitalizations. Parenteral nutrition utilization 
remained stable from 1997 to 2012. Our results confirm that PN 
is associated with a clinically and statistically increased risk of 
thrombus, infection, and composite complication in both CD 
and UC. Lastly, our study demonstrated that the presence of 
an abdominal surgical procedure during hospitalization is an 
independent risk factor for these PN-associated adverse events.
Our study’s findings emphasize the need for careful con-
sideration of PN use in pediatric IBD hospitalizations, partic-
ularly those hospitalizations involving an abdominal surgical 
procedure. A prior study of adult IBD revealed a 6.8% absolute 
risk of thrombus associated with peripherally inserted central 
catheters (PICCs), frequently present in the setting of PN use. 
In this study, the authors did not find a statistical difference 
in the prevalence of thrombus between patients with a CVL 
exposed to PN vs those with a CVL who were unexposed.12 
TABLE 3A. Multivariable Analysis, OR and 95% CI of Thrombus Among Pediatric IBD Hospitalizations for CD, UC, and 
Total IBD in the 1997–2012 KID Database
Characteristics Crohn’s Disease Ulcerative colitis All IBD
OR 95% CI OR 95% CI OR 95% CI
Parenteral nutrition 5.7 3.9–8.4 3.2 2.2–4.8 4.3 3.2–5.7
Age category, y
 <6 Ref Ref Ref
 6–12 0.4 0.1–1.5 0.7 0.2–1.7 0.6 0.3–1.3
 12–18 1.0 0.3–2.8 1.5 0.7–3.4 1.3 0.7–2.5
Female 0.6 0.4–1.0 1.3 0.9–1.9 0.9 0.7–1.2
Race category
 White Ref Ref Ref
 Black 0.8 0.4–1.5 1.3 0.7–2.3 1.0 0.6–1.5
 Hispanic 0.9 0.4–2.0 0.2 0.1–0.7 0.5 0.3–0.9
 Other 1.2  0.5–2.6 1.6 0.9–2.9 1.4 0.8–2.2
Payer type
 Medicaid 1.4 0.9–2.2 1.2 0.7–1.9 1.3 0.9–1.8
 Private/HMO Ref Ref Ref
 Other 1.2 0.6–2.6 0.3 0.1–1.2 0.8 0.4–1.4
Presence of a surgical procedure 1.6 1.0–2.6 2.3 1.5–3.5 2.0 1.5–2.6
Hospital type
 Rural 0.2 0.7 0.5
 Urban/nonteaching 1.3 0.03–1.8 0.7 0.2–2.1 1.0 0.2–1.3
 Urban/teaching Ref 0.8–2.1 Ref 0.4–1.3 Ref 0.7–1.4
Year
 1997 Ref Ref Ref
 2000 1.2 0.3–4.3 0.5 0.2–1.6 0.8 0.3–1.8
 2003 2.4 0.8–7.3 0.6 0.2–1.7 1.3 0.6–2.6
 2006 2.9 1.0–8.7 0.9 0.3–2.1 1.6 0.8–3.1
 2009 1.8  0.6–5.5 1.5 0.6–3.2 1.6 0.8–3.1
 2012 3.3  1.2–9.5 1.6 0.7–3.4 2.2 1.2–4.1
Disease type
 UC NA NA 1.8 1.4–2.3
 CD Ref
Receipt of PN in this study was determined by the indication 
reported for placement of the CVL. It therefore may have 
underestimated the number of PN-exposed patients who ini-
tially received the CVL for indications other than PN but who 
were ultimately exposed. In contrast to these adult data, our 
data reflect a lower absolute risk (3%) of thrombus in the hos-
pitalized pediatric IBD population studied, likely due to the 
well-described age-dependent risk of thrombus in the general 
population18 and IBD populations.19
The adult literature also suggests that PN is associated 
with an increased risk of infection. Using data from a nation-
ally representative inpatient database, the Nationwide Inpatient 
Sample, Ananthakrishnan et al. demonstrated a 2-fold risk of 
infections associated with the use of PN, although this study 
did not present data on absolute risks.20
The pediatric literature regarding the risks associated 
with PN among IBD patients is more limited. Nylund et  al. 
previously described the increased risk of thrombotic events in 
hospitalized children with IBD using the KID database.5 In that 
study, the authors identified PN as a risk factor for thrombus 
formation. Our work both confirms and extends these earlier 
findings. Our results are novel as they highlight the association 
between PN use and both thrombus and infectious outcomes 
using absolute risk, risk difference, and NNH associated with 
PN—the critical inputs of evidence-based medicine and clin-
ical decision-making. Our results reinforce the need to con-
sider age-specific risk and avoid extrapolation of risk estimates 
taken from adult studies. Our data may be used to inform cli-
nicians and families in decision-making regarding the initiation 
of PN for inpatient nutrition management in pediatric IBD 
TABLE 3B. Multivariable Analysis, OR and 95% CI of Infection Among Pediatric IBD Hospitalizations for CD, UC, and 
Total IBD in the 1997–2012 KID Database
Characteristics Crohn’s Disease Ulcerative Colitis All IBD
OR 95% CI OR 95% CI OR 95% CI
Parenteral nutrition 3.5 2.8–4.5 4.4 3.1–6.1 3.8 3.1–4.6
Age categories, y
 <6 Ref Ref Ref
 6–12 1.0 0.4–2.0 0.6 0.3–1.0 0.7 0.4–1.1
 12–18 1.1 0.5–2.2 0.5 0.3–0.9 0.7 0.4–1.1
Female 0.8 0.6–1.0 0.9 0.6–1.2 0.8 0.7–1.0
Race category
 White Ref Ref Ref
 Black 1.5 1.1–2.1 1.3 0.7–2.3 1.5 1.1–1.9
 Hispanic 1.1 0.7–1.7 1.6 1.0–2.5 1.3 0.9–1.7
 Other 1.2 0.7–2.0 1.4 0.7–2.4 1.3 0.9–1.9
Payer type
 Medicaid 1.2 0.9–1.7 1.4 0.9–2.1 1.3 1.0–1.6
 Private/HMO Ref Ref Ref
 Other 1.8 1.2–2.7 1.3 0.7–2.5 1.6 1.2–2.3
Presence of a surgical procedure 2.2 1.7–2.9 3.0 2.1–4.3 2.5 2.0–3.1
Hospital type
 Rural 1.0 0.5–1.8 1.2 0.5–2.8 1.0 0.6–1.7
 Urban/nonteaching 0.9 0.7–1.3 0.9 0.6–1.5 0.9 0.7–1.2
 Urban/teaching Ref Ref Ref
Year
 1997 Ref Ref Ref
 2000 0.6 0.3–1.1 0.6 0.3–1.4 0.6 0.4–1.0
 2003 1.2 0.7–2.0 1.0 0.5–1.9 1.1 0.7–1.6
 2006 1.0 0.6–1.7 0.8 0.4–1.6 0.9 0.6–1.4
 2009 1.1 0.7–1.8 0.7 0.3–1.3 1.0 0.6–1.4
 2012 1.0 0.6–1.6 0.7 0.4–1.4 0.9 0.6–1.3
Disease type
 UC 0.7 0.6–0.9
 CD NA NA Ref
hospitalizations. Our results are also strengthened by our use 
of a nationally representative data set for pediatric hospitaliza-
tions, thereby providing more generalizable conclusions than 
previously published single-center studies.17, 21
 An additional novel aspect of our study is the use of 
a composite outcome of either thrombus or infection associ-
ated with PN use. We believe this composite outcome serves 
as a clinically useful outcome to aid in clinical decision-mak-
ing. Indeed, an 8% absolute risk of PN related complications is 
high, resulting in a corresponding NNH of 17; however, prior 
studies have not evaluated the absolute risk of a composite out-
come, making it difficult to compare our findings with previous 
results.
We also identified that, among IBD hospitalizations ini-
tiating PN, the presence of an abdominal surgical procedure 
conferred a 2–3-fold risk of developing thrombus, infection, or 
the composite event. Though not robustly researched in pediat-
ric IBD, adult IBD studies have demonstrated an increased risk 
of both thrombus22 and infection20 in post–abdominal surgery 
adult IBD patients exposed to PN. Our results were statistically 
significant for all comparisons, with the exception of throm-
bus formation in the CD- and UC-stratified hospitalizations 
receiving PN. In both subgroups, we noted a numeric trend 
demonstrating elevated risk of adverse outcomes associated 
with surgical procedures. Though not statistically significant, 
each disease type demonstrated a 95% CI for hospitalization 
associated with the surgical procedure and adverse outcomes 
in those exposed to PN with lower bounds at 1.0. Despite this 
lower bound, adverse outcomes of thrombosis and infection in 
surgical hospitalizations remain a clinically significant problem. 
TABLE 3C. Multivariable Analysis, OR and 95% CI of Complication Among Pediatric IBD Hospitalizations for CD, UC, 
and Total IBD in the 1997–2012 KID Database
Characteristics Crohn’s Disease Ulcerative colitis All IBD
OR 95% CI OR 95% CI OR 95% CI
Parental nutrition 3.9 3.1–4.8 3.9 3.0–5.1 3.9 3.3–4.6
Age category, y
 <6 Ref Ref Ref
 6–12 0.8 0.4–1.5 0.6 0.4–1.1 0.7 0.4–1.0
 12–18 1.0 0.5–1.8 0.8 0.5–1.3 0.9 0.6–1.3
Female 0.8 0.6–1.0 1.0 0.8–1.3 0.9 0.7–1.0
Race category
 White Ref Ref Ref
 Black 1.4 1.0–1.8 1.3 0.9–2.0 1.3 1.1–1.7
 Hispanic 1.0 0.7–1.5 0.9 0.6–1.4 1.0 0.7–1.3
 Other 1.2 0.8–1.9 1.5 1.0–2.3 1.3 1.0–1.8
Payer type
 Medicaid 1.3 1.0–1.6 1.3 1.0–1.8 1.3 1.1–1.6
 Private/HMO Ref Ref Ref
Other 1.6 1.1–2.2 0.9 0.5–1.6 1.3 1.0–1.7
Presence of a surgical procedure 2.0 1.6–2.5 2.7 2.1–3.5 2.3 1.9–2.7
Hospital type
 Rural 0.8 0.4–1.5 1.0 0.5–2.0 0.9 0.6–1.4
 Urban/nonteaching 1.0 0.8–1.4 0.9 0.6–1.3 1.0 0.8–1.2
 Urban/teaching Ref Ref Ref
Year
 1997 Ref Ref Ref
 2000 0.6 0.4–1.1 0.6 0.3–1.2 0.6 0.4–1.0
 2003 1.3 0.8–2.1 0.9 0.5–1.6 1.1 0.8–1.6
 2006 1.2 0.7–1.9 0.8 0.5–1.5 1.0 0.7–1.4
 2009 1.2 0.8–1.9 1.0 0.6–1.6 1.1 0.8–1.5
 2012 1.3 0.8–1.9 1.0 0.6–1.7 1.1 0.8–1.6
Disease type
 UC 1.0 0.9–1.2
 CD NA NA Ref
Furthermore, hospitalizations associated with an abdomi-
nal surgical procedure likely involve sicker patients who may 
require longer exposure to PN, thus raising the absolute risk 
for adverse outcomes. As a result, development of thrombus or 
infection in these post–abdominal surgery IBD hospitalizations 
exposed to PN is a reasonable finding.
Our study has multiple strengths, including the use of a 
nationally representative sample of pediatric IBD hospitaliza-
tions to evaluate risks of PN use. The HCUP KID database pro-
vides a large sample size, facilitating a broad evaluation of the 
risks of PN use in pediatric IBD hospitalizations. Additionally, 
this regionally diverse and nationally representative database 
provided 15 years of data for analysis, allowing for trends in the 
prevalence of PN use to be reported on.
We acknowledge several limitations in our study. As with 
most epidemiologic studies that utilize administrative data, 
misclassification of patient condition, exposures, or outcomes 
identified by diagnosis or procedure codes is always possible. 
Despite this limitation, the KID database has been widely used 
in studies of pediatric IBD.5, 23–26 Additionally, the use of the 
specific ICD-9 procedure code to identify PN exposure in the 
KID database and the adult Nationwide Inpatient Sample 
(NIS) is also well accepted in the medical literature.5, 27 Another 
limitation to our study was the inability to measure and control 
for disease severity, prior PN use, and prior hospitalizations. 
Although we considered adjusting for additional clinical fac-
tors such as malnutrition and hypercoagulability, we decided 
against this given that the diagnosis codes were recorded in 
less than 1% of the entire sample, raising questions about 
validity. Thus, there is the potential for unmeasured confound-
ing by indication, as sicker patients may be more likely to be 
started on PN and more susceptible to thrombi and infection. 
Furthermore, our study did not distinguish between the use of 
peripheral PN and central PN. Hence, differentiation between 
the risk of peripheral PN and central PN is beyond the scope 
of this manuscript, though prior studies have observed the risk 
of infections with peripheral PN to be quite small (0.1–0.5 per 
1000 catheter-days).28 Additionally, the KID database does not 
contain data regarding medication dispensing. Hence, we could 
not account for the use of thrombus prophylaxis in our anal-
yses. Lastly, we acknowledge a number of limitations related 
to the cross-sectional structure of the KID database. First, the 
KID is structured at the level of the individual discharge rather 
than the individual patient. Thus, we could not differentiate 
between admissions for unique patients vs patients admitted 
multiple times. This may have slightly overestimated the risk 
of PN on thrombosis and infection. We also could not differ-
entiate between patients whose PN started before vs during 
their hospitalization. Similarly, we could not assess the tem-
poral relationship between the use of PN and the occurrence 
of thrombus and infection, though we speculate that thrombus 
and infection likely occurred after rather than before PN initia-
tion in most instances.
 In summary, we used a nationally representative sample 
of pediatric IBD hospitalizations to demonstrate that PN use in 
hospitalized patients is associated with an increase in absolute 
risk for thrombus, infection, and composite complication. In 
pediatric IBD hospitalizations involving PN, the presence of an 
abdominal surgical procedure is independently associated with 
an increase in the risk for adverse outcomes as well. Moving for-
ward, these data can be used to inform risk–benefit trade-offs 
in the nutritional management of hospitalized pediatric IBD 
patients and can contribute to the development of clinical prac-
tice guidelines for the inpatient nutritional management of this 
patient population, with the ultimate goal of delivering safer, 
more effective care through risk awareness and management. At 
a minimum, these data emphasize the need for judicious use of 
intravenous nutrition, particularly in abdominal surgical patients.
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
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